Reporter April 2 2021

Study links ADHD pharmacotherapy and retention rates for substance use disorder treatment

Kristopher Kast, MD, assistant professor in the Department of Psychiatry and Behavioral Sciences and clinical director of Vanderbilt’s Addiction Consult Service, has discovered a strong association between attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy and retention rates for substance use disorder (SUD) treatment.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Investigational vaccine to be tested against COVID-19 variant

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

COVID-19 met with intensive teamwork

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.

Novel way to neutralize Rift Valley Fever Virus

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Zach Lloyd spent 95 days on extracorporeal membrane oxygenation, or ECMO, after contracting COVID-19.

COVID recovery included long stay on ECMO, double-lung transplant

Zach Lloyd was only 37 years old with no pre-existing health conditions, but COVID-19 was bringing him within an inch of his life.

Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

1 2